Chiara Zuiani

Prof. Dr. Chiara Zuiani


Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 August 2017 in European Journal of Radiology
Verified
Journal Article
Closed access
RGRossano Girometti
Rossano Girometti
MPMartina Pancot
Martina Pancot
GCGiuseppe Como
Giuseppe Como
CZChiara Zuiani
Chiara Zuiani

18 March 2022 in European Journal of Radiology
Verified
Journal Article
Closed access
RGRossano Girometti
Rossano Girometti
ABAlfredo Blandino
Alfredo Blandino
CZClara Zichichi
Clara Zichichi
GCGiuseppe Cicero
Giuseppe Cicero
Lorenzo CereserLorenzo Cereser
Lorenzo Cereser
GGGianluca Giannarini
Gianluca Giannarini

9 November 2021 in British Journal of Radiology
Verified
Journal Article
Open access
RGRossano Girometti
Rossano Girometti
GGGianluca Giannarini
Gianluca Giannarini
VPValeria Panebianco
Valeria Panebianco
SMSilvio Maresca
Silvio Maresca
Lorenzo CereserLorenzo Cereser
Lorenzo Cereser
CVClaudio Valotto
Claudio Valotto
Objectives: To compare the effect of different PSA density (PSAD) thresholds on the accuracy for clinically significant prostate cancer (csPCa) of the Prostate Imaging Reporting And Data System v.2.1 (PI-RADSv2.1). Methods: We retrospectively included 123 biopsy-naïve men who underwent multiparametric magnetic resonance imaging (mpMRI) and transperineal mpMRI-targeted and systematic prostate biopsy between April 2019 and October 2020. mpMRI, obtained on a 3.0T magnet with a PI-RADSv2.1-compliant protocol, was read by two radiologists (>1500/>500 mpMRI examinations). csPCa was defined as International Society of Urogenital Pathology grading group ≥2. Receiver operating characteristic analysis was used to calculate per-index lesion sensitivity, specificity, and area under the curve (AUC) of PI-RADSv.2.1 categories after adjusting for PSAD ≥0.10,≥0.15, and ≥0.20 ng/mL ml−1. Per-adjusted category cancer detection rate (CDR) was calculated, and decision analysis performed to compare PSAD-adjusted PI-RADSv.2.1 categories as a biopsy trigger. Results: csPCa prevalence was 43.9%. PSAD-adjustment increased the CDR of PI-RADSv2.1 category 4. Sensitivity/specificity/AUC were 92.6%/53.6%/0.82 for unadjusted PI-RADS, and 85.2%/72.4%/0.84, 62.9%/85.5%/0.83, and 92.4%/53.6%/0.82 when adjusting PI-RADS categories for a 0.10, 0.15, and 0.20 ng/ml ml−1 PSAD threshold, respectively. Triggering biopsy for PI-RADS four lesions and PSAD ≥0.10 ng/mL ml−1 was the strategy with greatest net benefit at 30 and 40% risk probability (0.307 and 0.271, respectively). Conclusions: PI-RADSv2.1 category four with PSAD ≥0.10 ng/mL ml−1 was the biopsy-triggering cut-off with the highest net benefit in the range of expected prevalence for csPCa. Advances in knowledge: 0.10 ng/mL ml−1 is the PSAD threshold with higher clinical utility in stratifying the risk for prostate cancer of PI-RADSv.2.1 categories.

1 November 2015 in Pediatrics
Verified
Journal Article
Open access
PDF file
MMMarta Minute
Marta Minute
GPGiuseppa Patti
Giuseppa Patti
GTGianluca Tornese
Gianluca Tornese
EFElena Faleschini
Elena Faleschini
CZChiara Zuiani
Chiara Zuiani
AValessandro ventura
alessandro ventura
Congenital hyperinsulinism (CHI) due to diffuse involvement of the pancreas is a challenging and severe illness in children. Its treatment is based on chronic therapy with diazoxide and/or octreotide, followed by partial pancreatectomy, which is often not resolutive. Sirolimus, a mammalian target of rapamycin inhibitor, was reported to be effective in treating CHI in infants. We report here the case of an 8-year-old boy affected by a severe form of CHI due to a biallelic heterozygous ABCC8 mutation who responded to sirolimus with a dramatic improvement in his glucose blood level regulation and quality of life, with no serious adverse events after 6 months of follow-up. To the best of our knowledge, this is the first report of a successful intervention in an older child. It provides a promising basis for further studies comparing sirolimus with other treatments, particularly in older children.

12 July 2016 in La radiologia medica
Verified
Journal Article
Closed access
PDF file
GMGiovanna Mariscotti
Giovanna Mariscotti
PBPaolo Belli
Paolo Belli
DBDaniela Bernardi
Daniela Bernardi
BBBeniamino Brancato
Beniamino Brancato
MCMassimo Calabrese
Massimo Calabrese
FSFrancesco Sardanelli
Francesco Sardanelli